Boston Scientific Corp (NYSE:BSX)

$ 101.9 +0.76 (+0.75%) Market Cap: 150.72 Bil Enterprise Value: 161.68 Bil PE Ratio: 74.38 PB Ratio: 6.90 GF Score: 81/100

Q1 2025 Boston Scientific Corp Earnings Call Transcript

Apr 23, 2025 / 12:00PM GMT

Release Date Price: $98.92 (+4.07%)

Transcript 8-K

Key Points

Positve

Boston Scientific Corp (BSX) reported a strong Q1 2025 with operational sales growth of 22% and organic sales growth of 18%, exceeding guidance.
Adjusted EPS for Q1 2025 was $0.75, a 34% increase, surpassing the guidance range.
The company raised its full-year 2025 organic growth guidance from 10%-12% to 12%-14%, reflecting strong performance in its cardiology portfolio.
Electrophysiology sales grew 145%, making Boston Scientific the number two player globally in this segment.
The company received credit rating upgrades to A- from both Standard & Poor's and Fitch Ratings, indicating strong financial health.

Negative

Boston Scientific faces a $200 million tariff impact in 2025, primarily affecting the second half of the year.
The Cardiac Rhythm Management segment showed only 1% growth, slightly below market expectations.
The Urology segment experienced supply chain issues, leading to backorders and impacting growth.
Foreign exchange headwinds negatively impacted Q1 2025 revenue by 130 basis points.
The company anticipates a potential 200-300 basis point increase in its tax rate in 2026 due to the sunsetting of the TCJA.

Operator

Good morning, and welcome to the Boston Scientific first-quarter 2025 earnings call. (Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to Jon Monson, Senior Vice President, Investor Relations. Please go ahead.

Jonathan Monson

Boston Scientific Corp - Senior Vice President - Investor Relations

Thank you, Drew, and thanks, everyone, for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Dan will be joined by our Chief Medical Officer, Dr. Ken Stein.

We issued a press release earlier this morning announcing our Q&A results, which included reconciliations of the non-GAAP measures used in this release. The release, as well as reconciliations of the non-GAAP measures used in today's call, can be found on the Investor Relations section of our website.

Please note, on the call, all operational revenue excludes the impact of foreign

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.